New research suggests that workers exposed to welding fumes may be at risk for developing brain damage in an area of the brain also affected in Parkinson's disease. The study is published in the April 6, 2011, online issue of Neurology, the medical journal of the American Academy of Neurology.
[More]
Patients with advanced non-small cell lung cancer can safely take an experimental oral drug intended to protect healthy tissue from the effects of radiation, according to a study led by researchers at the University of Pittsburgh Cancer Institute and published in this month's issue of Human Gene Therapy.
[More]
With the many forms of sugar available, from table sugar, to high-fructose corn syrup to agave and honey, understanding the differences between sugars and their effects on the body is not all sweet.
[More]
The most common type of breast cancer in older women - estrogen and progesterone receptor positive breast cancer - has been linked to a protein that fends off aging-related cellular damage.
[More]
Sensitive new quantitive methods could be used to detect small signs of increased tremor and impaired motor skills caused by exposure to certain metals, and to follow up the treatment of neurological disorders, reveals a thesis from the University of Gothenburg, Sweden.
[More]
A team of researchers led by Maryse Bouchard, adjunct professor at the Center for Interdisciplinary Research in Biology, Health, Environment and Society (CINBIOSE) of the Universit du Qu-bec Montr-al and a researcher at Sainte Justine University Hospital, and Donna Mergler, professor emerita in the Department of Biological Sciences and a member of CINBIOSE, recently completed a study showing that children exposed to high concentrations of manganese in drinking water performed worse on tests of intellectual functioning than children with lower exposures.
[More]
Aeolus Pharmaceuticals, Inc. announced today that it has completed a $1.0 million financing with two existing institutional shareholders, both of which are affiliates of Xmark Opportunity Partners, LLC.
[More]
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
[More]
1st International Symposium on Deuterium Depletion was held on 13-14 May 2010 in Budapest, Hungary. The conference programme focused on the advances in the research and clinical application of deuterium depletion, its present and future role in anticancer research and oncotherapy, diabetes research and anti-aging.
[More]
Aeolus Pharmaceuticals, Inc. announced today that a second study of its lead drug, AEOL 10150, has been initiated by the National Institutes of Health's (NIH), National Institute of Allergy and Infectious Diseases (NIAID) Radiation/Nuclear Medical Countermeasures development program as a countermeasure for radiation exposure to the gastrointestinal (GI) tract.
[More]
The largest epidemiological study of Parkinson's disease in the United States has found that the disease is more common in the Midwest and the Northeast and is twice as likely to strike whites and Hispanics as blacks and Asians.
[More]
New York subway commuters may worry more about rats and rising fares than dust floating through the system, but for the workers who spend their whole shift below ground, air quality has long been a concern. Results from a new pilot study using miniaturized air samplers to look at steel dust exposure may help them breathe easier.
[More]
Aeolus Pharmaceuticals, Inc. announced today that after review of the Company’s white paper on development of AEOL-10150 as a countermeasure for the lung effects of acute radiation syndrome, the Biomedical Advanced Research and Development Authority (BARDA) Division of Chemical, Radiological and Nuclear (CBRN) Countermeasures has informed the Company that, after careful analysis and consideration, it has invited Aeolus to submit a full proposal for a contract to develop AEOL 10150 from its current level of technical readiness to FDA approval.
[More]
Aeolus Pharmaceuticals, Inc. announced today financial results for the three months and twelve months ended September 30, 2009. The Company reported a net loss of $746,000, or $0.02 per share, for the three months ended September 30, 2009 compared to a loss of $1,055,000, or $0.03 per share, for the three months ended September 30, 2008.
[More]
Reportlinker.com announces that a new market research report is available in its catalogue: The Market for Anti-ageing Foods (2nd Edition)
[More]
Physicians for Social Responsibility today released a groundbreaking medical report, "Coal's Assault on Human Health," which takes a new look at the devastating impacts of coal on the human body.
[More]
Aeolus Pharmaceuticals, Inc. announced today the initiation of a study to test the anti-tumor effects of AEOL 10150 when combined with radiation and chemotherapy in nude mice bearing human non-small cell lung cancer (NSCLC) xenografts.
[More]
Aeolus Pharmaceuticals, Inc. announced today that recent experiments in preclinical models conducted by the National Institutes of Health’s (NIH), National Institute of Allergy and Infectious Diseases (NIAID) Radiation/Nuclear Medical Countermeasure Development program have shown that AEOL 10150 can effectively increase regeneration of gastro-intestinal (GI) stem cells, reduce the severity and duration of diarrhea and improve survival when administered at 24 hours after doses of total-body irradiation that produce the lethal GI syndrome.
[More]
Wells are used to extract water from aquifers, natural underground stores of water found on layers of permeable rock, gravel or clay. The water is pumped up and transported via pipes to treatment works, where it is cleaned and filtered through gravel beds before being conveyed to domestic and business consumers via a network of smaller pipes or mains.
[More]
Aeolus Pharmaceuticals, Inc. announced today that it has completed a $1.65 million financing with several existing institutional shareholders, all of which are affiliates of Xmark Opportunity Partners, LLC. Under the terms of the financing, Aeolus received $1.65 million in gross proceeds in exchange for 5,892,857 Units (the “Units”), with each Unit comprised of one share of Aeolus Pharmaceuticals common stock, and a seven year warrant to purchase up to two additional shares of Aeolus Pharmaceuticals common stock at an initial exercise price of $0.28 per share, for a per Unit purchase price of $0.28.
[More]